KSQ Therapeutics rakes in $80 mln Series C
Cambridge, Massachusetts-based drug developer KSQ Therapeutics has secured $80 million in Series C financing. The investors included Baillie Gifford, Cowen Healthcare Investments, Invus, Lilly Asia Ventures, Flagship Pioneering, Polaris Partners, ARCH Venture Partners and Alexandria Equities.
28 September 2018•1 min read
